CryoPort Inc (CYRX)

[H2R]

SEC Form 4: Shelton Jerrell exercised 65,250 shares at a strike of $2.90 and sold $4,251,176 worth of shares (65,250 units at $65.15) as part of a pre-agreed trading plan

This seems to be the reason for the 8% drop today, as far as I can tell.

Best of luck with your investments!

[Eggplant]

Not bad, Mr. Eggplant - you wrote: "Until then, I expect insiders keep selling, and I would expect Blackstone to look for a quicker out." Blackstone filed a 13-d showing disposal of another 500k shares - I think that was 25% of their remaining position. Not certain. CEO Jerrell Shelton also sold > $5m of stock.

[ConstitutionNow]

Hello H2R, been checking in periodically checking in to see if anyone is paying attention to us yet. You are a consistsnt poster which I appreciate. Nothing from Larry S lately, hope he's doing alright.

Eggplant brings up a nagging issue for me also, as the growth outside acquisitions is fairly slow. The reason I'm still here after all these years is Cryoport is the gold standard for logistics in the still young immunotherapy industry. To be honest I feel like they are being helped by the industry as far as share price support and funding. The industry would really struggle without a reliable 'partner' for logistics. So they may be getting fed money at higher stock prices to build out their support network.

I am anticipating they have another acquisition in their sites due to this latest money raise pr, which may give us another boost. I'm glad to see them take advantage of the high stock price when the opportunity presents.

Thanks again for your perspective, always helps to see what others see. I'm sure I'll be here for a few years yet!

[H2R]

Hi Eggplant :)

You write:

The capital raising transactions announced after the close today appears highly opportunistic

CYRX seems to keep looking for acquisition and for that, they need to have the ability to raise funds. From the CC, I think they keep looking at opportunities in APAC, and especially in China.

In terms of growth, I like your idea of the next earnings report to really see the organic growth of the integrated company, 'apples to apples'. And I can wait :)

As for me, I am impressed with the 'pipeline' of clinical trials and what percentage / when that will translate into commercial products relying on their logistics chain. I have a long timeframe for that company.

So far, I'm up 716%. I can take some pullbacks on this one, I doubt I'll take plunge.

Thanks for your thoughts!

Best of luck with your investments!

[Eggplant]

Q3 was a bit weird they way they reported it. Yes: "On an organic basis that is without acquisitions, this translates into 38% year-over-year growth". But, 73% of the Q3 revenue was from acquisitions - the two major acquisitions that closed on 10/1/20. THOSE acquired businesses, actually showed a slight negative revenue growth from 2Q21 to 3Q21. When asked about seasonality on the call, mgt kind of faded and hedged. Reality: it looks like the majority of CYRX's business revenue isn't growing at all, or is only at a very moderate rate.

The capital raising transactions announced after the close today appears highly opportunistic: they had $350m of excess cash at 9/30/21 - the vast majority of that was raised opportunistically last January when the stock spiked to $66. The complex transactions involving convertible and stock issuance and old convertible repurchase allows CYRX to raise $300m of additional cash (plus a shoe?) and allows the old convert holders to role into the new issue without have to unwind and then reset hedging transactions. JeffCo gets the nod - they had the highest stock price target from their equity analyst: $96. Well, that's normal.

Q4 results probably won't get reported until next March. I think that is when the true apples to apples comparison of businesses will reveal there really isn't any, or at least very much, "there" there, in this would be growth story. Until then, I expect insiders keep selling, and I would expect Blackstone to look for a quicker out.

"Overall, we had a revenue increase of 371% over the third quarter of 2020." Really? - I calculate a 407% increase over Q3 2020 - but the number is largely meaningless because nearly 3/4's of Q3 revenue was acquired and is being compared to a prior year base of $0 under acquisition accounting.

[H2R]

Proposed offering.


Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering
NASHVILLE, Tenn., Nov. 8, 2021 /PRNewswire/

Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its intention to offer, subject to market and other conditions, $300,000,000 aggregate principal amount of convertible senior notes due 2026 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Cryoport also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $45,000,000 principal amount of notes.


The notes will be senior, unsecured obligations of Cryoport, will accrue interest payable semi-annually in arrears and will mature on December 1, 2026, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Cryoport will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Cryoport's election. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Cryoport's option at any time, and from time to time, on or after December 6, 2024 and on or before the 41st scheduled trading day immediately before the maturity date, but only if certain liquidity conditions are satisfied and the last reported sale price per share of Cryoport's common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

Cryoport intends to use the net proceeds from the registered direct placement of common stock referred to below and a portion of the net proceeds from the offering to repurchase a portion of its outstanding 3.00% Convertible Senior Notes due 2025 (the "2025 convertible notes") in separate, privately negotiated repurchase transactions with a limited number of holders of the 2025 convertible notes. Cryoport intends to use the remainder of the net proceeds for general corporate purposes.

Holders of the 2025 convertible notes that participate in any of these repurchases may purchase or sell shares of Cryoport's common stock in the open market to unwind any hedge positions they may have with respect to the 2025 convertible notes or to hedge their exposure in connection with these transactions. These activities may adversely affect the trading price of Cryoport's common stock and the notes being offered. Moreover, market activities by holders of the 2025 convertible notes may impact the initial conversion price of the notes being offered.

In a separate press release, Cryoport also announced today its intention to offer, subject to market and other conditions, shares of common stock in a separate, registered direct placement. The completion of the offering of the notes is not contingent on the completion of the placement of common stock; however the completion of the placement of common stock is contingent on the completion of the offering of the notes. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any common stock in the placement.

http://ir.cryoport.com/news-releases/2021/11-08-2021-213402900

[H2R]

Supports 70 Ph 3, 25 MAA or BLAA til EoY 22

Our pipeline of commercial customers is the largest in our history. We’re now supporting 582 regenerative medicine clinical trials was 70 of them in Phase 3, approximately 30% of our pipeline is allogeneic of which 32 are in Phase 3.

We’re currently supporting eight commercial therapies and regenerative medicine. And for the remainder of this year, we anticipate up to another four MAA or BLA submissions for Cryoport supported products. In 2022, we’re looking for up to 21 additional filings. On the financial front, our total revenue in the third quarter of 2021 was a record $56.7 million, up from $11.2 million in the same period of the prior year.

On an organic basis that is without acquisitions, this translates into 38% year-over-year growth as we’re total revenue and the period, our Biopharma/Pharma business continues to be strong accounting for approximately 81%. Overall, we had a revenue increase of 371% over the third quarter of 2020.

CC Nov 4, 2021

[H2R]

582 clinical trials and 8 commercial therapies in regenerative medicine

Note: In August 2021: a record 561 clinical trials, compared with 543 at the end of the first quarter of 2021 and 491 at the end of the second quarter of 2020



Earnings Report Nov. 4th, 2021 highlights:

- Third quarter revenue increased 407% year over year, reaching $56.7 million; Nine Months 2021 revenue $166.2 million

- Organic Revenue Growth of 38% coupled with continuing strong performance by MVE Biological Solutions and CRYOPDP

- Now supporting a record 582 clinical trials and eight commercial therapies in regenerative medicine

Net loss attributable to common stockholders was $8.5 million, or $0.18 per share, for the third quarter of 2021, compared to a net loss attributable to common stockholders of $11.4 million, or $0.29 per share, for the third quarter of 2020.

This loss reflects a paid-in-kind dividend of $2.0 million and $6.2 million during the third quarter and nine months ended September 30, 2021, respectively, resulting from the private placement of Series C Preferred Stock with the Blackstone Group, completed in connection with the MVE Biological Solutions acquisition.

CYRX keeps building a juggernaut growth engine.

Full details:
http://ir.cryoport.com/news-releases/2021/11-04-2021-201106440

[H2R]

CRYOPDP: 2021 Europe Bioprocessing Excellence Award from IMAPAC

http://ir.cryoport.com/news-releases/2021/10-29-2021-153029109

CRYOPDP, a Cryoport Company, Receives 2021 Europe Bioprocessing Excellence Award from IMAPAC

CRYOPDP, a Cryoport Company, named as 'The Company You Need to Watch Out For in 2022'

NASHVILLE, Tenn., Oct. 29, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its wholly-owned operating company, CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, biopharmaceutical and cell and gene therapy markets, headquartered in Paris, France has been recognized as winner of the award, 'The Company You Need to Watch Out For in 2022' at the Europe Bioprocessing Excellence Awards 2021. The virtual awards ceremony held in conjunction with the Biologics Contract Manufacturing Europe 2021 and 4th Biologics World Nordic 2021 on October 28, 2021 was attended by over 800 guests representing more than 150 organizations within Europe across 30 different biological product manufacturing categories.


The Europe Bioprocessing Excellence Awards seeks to grant recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality. Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Europe Bioprocessing Excellence Awards applauds extraordinary leaders and trend-setters of today and inspires innovators of tomorrow.

CRYOPDP is located in 23 global facilities in 14 countries and has more than 25 years of experience serving the life sciences and healthcare industries, providing customized and turnkey premium logistics and transport solutions, with over 300,000 high-value, time critical annual shipments globally. CRYOPDP covers a significant portion of the healthcare temperature-controlled supply chain including premium services, packaging, pick-pack kit preparation and specialty courier support, as well as premium added value solutions such as LabMove, DtP and Control Tower, a fully integrated project management solution.

"We are humbled by and grateful for this prestigious award, being recognized as 'The Company You Need to Watch Out For in 2022,'' said Cedric Picaud, CEO of CRYOPDP. "It is a great honor for the company to be in this position and it speaks volumes about our remarkable team and the work they are carrying out in fulfilling our mission to improve the health of the people around the world."

Jerrell Shelton, President and Chief Executive Officer of Cryoport, added, "As Cryoport continues to grow and evolve, we have been laser-focused on delivering the highest quality solutions and service to our global customers. This award is a testament to our innovation and expertise in bioprocessing and biomanufacturing

Best of luck with your investments!

[Frozen asset]

Nice on NWBO. You’ve got me beat on NWBO, I got in at $0.33 and $0.75. I’ve done so much due diligence on them and am a little baffled why they seem to be languishing but I guess it has been an awfully long journey (but for good reason in my opinion). Thanks for your two cents. There’s so much posted and passion on that board I was looking for some less emotional opinion. Good luck on your investments and go NWBO! Interesting run at the end of the day today…

[H2R]

Dang, since $2. Nice!! I started around $10, and I am quite happy with the return :))

I'm waiting for the next CC which is planned as of now for Nov. 4th and check their status.

CYRX is executing on growth strategy based on the clinical trials, which feeds eventually into commercial products with much greater revenue, and an expansion strategy with partnering or acquisition for greater territory coverage. It's hard to see them fail, it's just a question of how fast they grow and the EPS turns.

On NWBO, the wait is really long, but with the blended data article I cannot see how the trial with the 'new' endpoints can fail. I believe they have access to funds from different sources, including (very) wealthy individuals who can make sure NWBO does not go BK before top line data/ journal publication. Even if they are really slow, I am betting on positive TLD, journal articles, other news (GMP approval, etc.) to hold up the PPS after TLD, and BLA (in the UK / MHRA first?). It's really long, but I believe it will be quite the return and a positive impact in the fight against cancer (I am in at around $0.27, so already a great return :) ).

Wishing you the best with your investments,

Cheers!

[Frozen asset]

Hey H2R, I’ve held CYRX since $2 and appreciate your posts. I’m shocked there aren’t more conversations going on here. I also hold NWBO and I’ve seen you post a few times there. I feel like NWBO has the same kind of potential as CYRX. I’m curious to your thoughts. Thanks again for your posts over the years.

[H2R]

80 in play! The PPS has been pushing up lately. Earning report next week.
Best of luck with your investments!

[H2R]

Looking forward to the Q3 CC!

The (unconfirmed) Q3 earning is planned for 11/03/2021. This should show how the execution of the strategy is unfolding.

The documents around the Cc: http://ir.cryoport.com/events-and-presentations

Best of luck with your investments!

[H2R]

Cryoport Creating 'High Bar for Competitors' -- Market Talk
BY Dow Jones & Company, Inc.
— 4:13 PM ET 10/19/2021
1613 ET - B. Riley Securities resumes coverage on temperature-controlled supply chain solutions company Cryoport Inc. ( CYRX ) at buy with a price target of $81. Cryoport has built integrated services, "especially augmenting its operational excellence by supporting 500+ clinical trials and 8 commercial cell & gene therapies," with a greater-than 99% success rate for shipments, the analysts say. Although Cryoport doesn't have the highest volume among peers, "CYRX wins on the quality of service, which has created a high bar for competitors to overcome," says the investment bank. B. Riley points to continued expansion in the cell & gene therapies landscape and sustained tailwinds from regulatory policy as key drivers for CYRX's long-term growth prospects. Shares finished up 3.2%. ([e-mail])

Others are seeing the growth ramp based on the number of supported clinical trials with some % ending up commercial. You can see the future right there for CYRX.

Best of luck with your investments!

[H2R]

SA Article on CYRX valuation: 45% upside

https://seekingalpha.com/article/4457983-cryoport-unfairly-punished-valuation-update-shows-45-percent-upside

Lots of ways to look at the valuation and the growth in this article. The growth is what I am most interested in and that's very much in line with the way I see it too.

We are bullish on Cryoport, Inc. (NASDAQ:CYRX) shares and see an investment case that is backed by robust revenue growth, an accelerated FCFF growth period, and a visible path to profitability as additional cell and gene therapies become commercialised in the coming decade. Additionally, acquisitions made by the company last year, appear accretive to its top and bottom lines, and it is not an unreasonable expectation to foresee Cryoport engaging in further acquisition activity, targeting high margin names or complimentary product lines that tuck into its portfolio mix.

On this point we note that Cryoport is now supporting 561 clinical trials, of which 69 of these are phase 3 stages. This is up by around 20 trials from the previous quarter. As such, the company is now expecting up to nine MAA or BLA submissions from its clients in the second half of this year, with up to 12 submissions expected in 2022. Given the 69 phase 3 trials, regulatory catalysts are no doubt on the way as key inflection points for Cryoport's share price.

Best of luck with your investments!

[H2R]

Cryoport and Mitsubishi Logistics Corporation Partner to Bring Temperature-Controlled Supply Chain Solutions to Asia-Pacific

CYRX continues on its expansion strategy!

NASHVILLE, Tenn., Aug. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation ("MLC"), Japan's leading pharma logistics company, today announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.


Cryoport and MLC will partner to create synergistic value by leveraging each other's global logistics networks. The partnership will provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution. MLC has chosen to adopt Cryoport's unique and proprietary temperature-controlled and traceability solutions to meet the increasing demand for cell and gene therapy supply chain solutions and to strengthen its logistics capabilities.

Mr. Masao Fujikura, President of MLC said, "This strategic alliance will strengthen our ultra-low temperature-logistics services for our valued customers both domestically and internationally, utilizing Cryoport's proprietary technologies for cell and gene materials."

Jerrell Shelton, CEO of Cryoport, said, "This strategic alliance furthers our expansion strategy in the Asia-Pacific ("APAC") region. MLC and Cryoport will encourage the use of each other's network, infrastructure, knowledge and resources to enhance each other's operational performance and to generate value for customers in Japan and overseas to meet demand from the increasing number of cell and gene therapies currently in development and expected to launch in coming years. Combining both companies' strengths is expected to realize reliable and seamless distribution services for biopharmaceutical and pharmaceutical companies in Japan and the APAC region."

As of June 30, 2021, Cryoport supported 561 clinical trials in regenerative medicine globally, 29 of which are in the APAC region. In addition, a number of therapies supported by Cryoport have recently been approved in the APAC region, including Novartis' commercial therapy KYMRIAH®, which is approved in Japan, Singapore and Australia and Bristol Myers Squibb's commercial therapy BREYANZI®, which was approved in Japan. Cryoport is continuing to build out its position to support the growing number of commercial therapies in anticipation of the next wave of expected commercial approvals in the APAC region.

[H2R]

$2M - $28M per (additional) commercial product support!

Jacob Johnson

Got it. Thanks for that, Robert and Mark. And then I guess this is my follow-up, just a kind of big picture question that you used to talk about $2 million to $20 million of revenues per commercial approval. I think that moved to $2 million to $28 million with the CRYOPDP and the MVE deals. you've owned these businesses, I guess for almost a year now. Can you just - it is almost $2 million to $28 million, so the expectation or have you found some additional opportunities that maybe, I guess maybe, give you more confidence in it or think that maybe, $2 million to $28 million something larger than that?

Robert Stefanovich

No. those ranges are not changing, Jacob and these therapies are just beginning to ramp. So, we're confident with our customers.

Based on the clinical stage in Phase 3 (69) and a percentage of success, say 70% or whatever number you pick, one can extrapolate the revenue curve. And then the 265 in Phase 2 with a % -> Phase 3 and a % -> commercial.

Best of luck with your investments!

[H2R]

F-airGate: Another acquisition I was not aware of.

CYRX keeps wanting to expand its global reach.

We also acquired F-airGate, a provider of innovative temperature-controlled supply chain solutions, headquartered in Brussels, Belgium, which supports our expansion of presence in the EMEA region. This adds - these additions to Cryoport are in strategic locations, where hundreds of cell and gene therapy trials are underway as well as an increasing number of commercial approvals, such as the marketing approval of KYMRIAH in Australia in February 2021.

[...]

In the second quarter, we also launched our new Cryoport Systems/CRYOPDP global logistics center in Osaka, Japan, where we - which we set to support our - excuse me, which we set up to support commercial launch activities and client needs that we believe will further accelerate growth in APAC. Our pledge of generating $100 million of revenue and cost synergies between CRYOPDP and Cryoport Systems is underway and proceeding on schedule.

https://seekingalpha.com/article/4446954-cryoport-inc-cyrx-ceo-jerrell-shelton-on-q2-2021-results-earnings-call-transcript

[H2R]

Q2 Growth Visual

[H2R]

Growth Funnel

This funnel is relentless :)



As trials move to clinical, CYRX prints money. Worldwide.

This stock is all about growth, with solid financials. It's just a question of time. And I have time.

[H2R]

$349.4 million in cash, cash equivalents and short-term investments as of June 30, 2021, compared with $93.3 million as of December 31, 2020. This amount includes net proceeds of approximately $269.8 million received from an underwritten public offering of 4,356,059 shares of its common stock, at a public offering price of $66.00 per share, during the first quarter of 2021.

http://ir.cryoport.com/~/media/Files/C/Cryoport-IR/documents/events/cryoport-q2-2021-in-review.pdf

[H2R]

a record 561 clinical trials, compared with 543 at the end of the first quarter of 2021 and 491 at the end of the second quarter of 2020,

and eight commercial therapies in regenerative medicine, including SKYSONA™, a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) by bluebird bio, which was granted marketing authorization by the European Commission on July 21, 2021.

http://ir.cryoport.com/news-releases/2021/08-05-2021-211017233

Talk about a growth story!

[H2R]

Organic Revenue Growth of 55% (ER Q2)

Record Revenue for Second Quarter of 2021 of $56.2 million
- Revenue increased 498% year over year, with continuing strong performance by MVE Biological Solutions and CRYOPDP
- Organic Revenue Growth of 55%
- Supporting a record 561 clinical trials and eight commercial therapies in regenerative medicine


NASHVILLE, Tenn., Aug. 5, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30, 2021.


Jerrell Shelton, CEO of Cryoport, commented, "This was another strong quarter with excellent performance across all our business units driving both year-over-year growth and sequential growth compared with our record-breaking first quarter. Our total revenue for the quarter grew to a record $56.2 million with CRYOGENE and Cryoport Systems delivering a 55% organic growth rate year-over-year coupled with strong respective results from MVE Biological Solutions and CRYOPDP. This outstanding performance reflects the continuing successful execution of our overall growth strategy, and we expect to continue this momentum throughout the second half of 2021 and beyond as our market engagement strategies for MVE Biological Solutions and CRYOPDP are driving increasing synergies to reinforce their growth. And, of course, revenue from our eight commercial agreements and our continuously growing support of next generation and groundbreaking clinical trials continues to fuel organic growth.

"Our position as a leading life sciences supply chain partner to the regenerative medicine market has never been stronger, with Biopharma/Pharma revenue increasing 431% year over year in the second quarter of 2021 or 51% organically.

http://ir.cryoport.com/news-releases/2021/08-05-2021-211017233

Growth!

[H2R]

New SoS post on CYRX:

The meaningful increase in today's price appears to be due to the reported approval of Gilead's CAR-T drug Yescarta in China.

On another matter, CEO Jerry Shelton (for whom I have great respect) has said that the company's goal is to reach $650 million of sales in 2025 through organic growth. Acquisitions could increase this. The Company reported 43.8 million shares outstanding in the latest 10-Q. In addition, it is likely that an additional 16.5 million shares could (and almost certainly will) be issued from options, warrants and convertible securities. So let's say that there are really 60.3 million shares outstanding. Based on current valuations of premier growth stocks like CYRX, I could see the stock selling at 20 to 30 times revenues in 2025, This translates into a $13 billion to $20 billion market capitalization. In stock price terms this would be $215 to $330 per share.

The detailed assumptions underlying this forecast have not been disclosed and needless to say current valuations may not be reflective of those in 2025. Take this with a grain of salt. I just thought I would throw it out.

https://smithonstocks.com/cryoport-strength-in-stock/

Best of luck with your investements!

[H2R]

No kidding. I'm staying long for probably another year or two, unless I see red flags. I'm not at the moment.

Best of luck with your investments!

[ConstitutionNow]

Yes, that's A LOT of oil in the ground to be tapped yet!

[ConstitutionNow]

Agreed, last I saw insider and tute ownership was ballpark 88%, so funny it crashed like that. That high a percent should really make it more stable, especially on low volume. Of course, it can and has gone up just as fast in the past. Still positive here though.

[H2R]

Volume: 320K shares ... PPS: -13%???

That's a weird combo. I don't see the news that would drive the PPS down like this. And on an average volume, that looks 'strange'.

Best of luck with your investments!

[Frayed Knot]

Certainly enjoying my CYRX investment.

[H2R]

Now 7 commercial therapies, including bluebird bio's and Bristol Myer Squibb's CAR-T therapy Abecma® and Bristol Myers Squibb's BREYANZI®

We continued to work closely with all our partners and clients to ensure patients have access to the life-saving therapies we support. Commercial revenue, to date, has been primarily the result of our global agreements supporting the ramp ups of Novartis's KYMRIAH® and Gilead/Kite's YESCARTA®. In addition, Bristol-Myers Squibb (BMS) has received US Food and Drug Administration (FDA) approval for its cell therapy BREYANZI®, and bluebird bio and BMS and have received FDA approval for their CAR T-cell therapy Abecma®, a first-of-its-kind CAR T-cell therapy for treatment of multiple myeloma. Cryoport will support both these groundbreaking therapies, marking Cryoport's sixth and seventh long-term agreements supporting the global commercial launch of a cell and gene therapy. We expect these agreements to contribute to our revenue in the second quarter of 2021 and will begin to ramp throughout 2021, driving additional growth in our commercial revenue in 2021.

[H2R]

543 clinical trials in regenerative medicine

That's why this is such a great company. The 'picks and shovels' of the gold rush!

Jerrell Shelton, CEO of Cryoport, said, "It was a strong quarter and it developed as we had anticipated. We entered 2021 with an unrivaled leadership position with market-leading temperature-controlled supply chain solutions for the life sciences industry in our markets of Biopharma/Pharma, Animal Health and Reproductive Medicine. Our global platform, consisting of 32 locations and a family of companies that provide mutually reinforcing solutions, services and products, delivered an outstanding performance. Cryoport's revenue grew to a record $53.3 million for the quarter with our recent acquisitions of MVE Biological Solutions and CRYOPDP contributing significantly as we navigated the ongoing integration of these two fine acquisitions.

I would like to emphasize that all our business units reported record revenue as well as strong sequential growth over our record fourth quarter 2020. This performance was primarily driven by the Biopharma/Pharma market, which represented approximately 80% of our total revenue in the first quarter of 2021.

It is notable that we continued to build out our pipeline of potential commercial customers with the total number of regenerative medicine clinical trials supported by Cryoport reaching a record 543 trials compared with 465 at the end of the first quarter of 2020 as well as adding 2 new commercial launches supported by Cryoport.

http://ir.cryoport.com/news-releases/2021/05-04-2021-210554092

[H2R]

Q1 Revenue Climbs to $53.3M!

http://ir.cryoport.com/news-releases/2021/05-04-2021-210554092

- Revenue increased 445% compared with Q1 2020, with acquisitions of MVE Biological Solutions and CRYOPDP driving significant growth
- Organic revenue growth of 35% compared with Q1 2020

Not too shabby!

Best of luck with your investments!

[H2R]

ASM: April 30th (DEFA14A)

On March 16, 2021, Cryoport, Inc. (the “Company”) filed a definitive proxy statement (the “Proxy Statement”) with the Securities Exchange Commission in connection with the Company’s Annual Meeting of Stockholders scheduled for April 30, 2021 (the “Annual Meeting”).

One of the few things highlighted in the DEFA14A is the # of employees, both in terms of growth, past and planned, and in terms of voting on #shares:

With the CRYOPDP and MVE Biological Solutions acquisitions, and through organic growth and other acquisitions, our global headcount increased by approximately 514 employees to approximately 654 from December 31, 2019 to March 10, 2021.

We expect to continue to grow, both organically and through acquisitions, and seek to provide new employees with equity incentives under the 2018 Plan. We believe that it is important for our stockholders to take a forward-looking view in how the plan can be used to incentivize the growing organization we expect to see in the coming years.

It is also important to note that annual grants made to employees are merit based and that the increase in the number of authorized shares under the 2018 Plan that would be made available by the approval of the Second Amendment is projected to be sufficient to cover the Company’s equity compensation needs for two or three years, although this could change based on factors including actual acquisition activity

http://archive.fast-edgar.com/20210421/ABBYI62C8Z22GZZ222JN2ZZZQMSOZ2V2N232/

Best of luck with your investments!

[H2R]

CYRX expands its global reach: APAC!

http://ir.cryoport.com/news-releases/2021/04-06-2021-133206815

Cryoport Acquires Temperature-Controlled Logistics Provider in Australia

Acquisition Further Expands Cryoport's Presence in Asia-Pacific Region to Address Increased Clinical Trial Activity Worldwide

NASHVILLE, Tenn., April 6, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has acquired Critical Transport Solutions Australia Pty Ltd ("CTSA"), a market leader in providing premium healthcare logistics management services, specializing in time- and temperature-critical solutions for the medical and pharmaceutical industries based in Australia, for approximately USD 5 million. CTSA will be a part of Cryoport's CRYOPDP business unit and will continue to be run by the current management team.


Acquiring CTSA's distribution capabilities in Australia is expected to improve Cryoport's position to gain market share in APAC (Asia Pacific) as the number of clinical trials taking place in the region continues to increase. The CTSA acquisition follows the opening of Cryoport Systems and CRYOPDP's first jointly operated global logistics center in Osaka, Japan, in the fourth quarter of 2020 and forms part of the Company's ongoing expansion strategy in APAC. As regenerative therapies' global emergence continues and trials evolve from clinical-stage to commercial-stage, Cryoport believes that its enhanced global platform further makes it the clear choice to support pharmaceutical/biopharmaceutical companies in bringing their regenerative medicine therapies to market.

Additionally, on January 28th, 2020 Cryoport's customer Novartis announced that Kymriah® will be publicly funded following a recommendation from the Medical Services Advisory Committee (MSAC) for the treatment of eligible adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in Australia. Novartis also announced an agreement with Cell Therapies to manufacture Kymriah at their production facility within the Peter MacCallum Cancer Centre in Melbourne. Cell Therapies is an Australia-based, globally active commercial contract development and manufacturing company, specializing in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products.

"Adding this new country into CRYOPDP's global network will enable the Cryoport Group of companies to develop additional synergies in this specific country, providing end-to-end Pharma/Biopharma Logistics Solutions to our global customers and the local players in Australia. "By this additional geographical coverage, we are also anticipating the fast growing needs of our top strategic customers, to better serve their expanded activities in this zone and to be always closer to patients. As a strong customer and patient centric organization our strategy is to continue to develop our geographical footprint," said Cedric Picaud, CEO, CRYOPDP.

"Our acquisition of CTSA is what I like to refer to as a tactical acquisition with strategic impact. It is an accretive acquisition providing us with an important foothold in Australia, which is a top five country in APAC for clinical trials and a strategic location from which we can build our client base in the region," said Jerrell Shelton, CEO, Cryoport. "The CRYOPDP team has worked closely with the CTSA team over the past two years. In that time, CTSA has proven its professionalism, client focus and commitment to providing exemplary service. Combining CRYOPDP's global distribution network with CTSA's regional capability is expected to increase our revenue base and provide economies of scale. We are confident that CTSA and its able operating team will be a strong addition to the Cryoport company portfolio in APAC."

There is a definite strategy at work.

Best of luck with your investments!

[H2R]

From $10 to $70 in ~ 2 years, playing with house money.

Not my worst stock :)

Best of luck with your investments!

[gmoney305]

still not $166 after 7 yrs and 2 r/s still a pos

[H2R]

SoS: Projected Growth

That's the part of the article that makes the most sense to me:

It is important to understand that Kymriah and Yescarta are just the first two therapies based on living cells to be approved.

There will be a tsunami of other cell based therapies that will come to market over the coming decades.

Market research cited by Cryoport projects that there could be somewhere between 56 and 129 unique new cell based therapies approved by 2027; I expect that Cryoport will support most of them.

In the near term, Cryoport said that its clients filed 7 MAAs/BLAs in 2020 and estimates they will file 23 more in 2021. An MAA/BLA can be a regulatory submission for a new product or a new indication for an existing product. Cryoport is poised for explosive growth.

https://smithonstocks.com/cryoport-cyrx-buy-72-30-kymriah-sales-are-strong-and-equity-offering-was-well-received/

[msrstocks]

That was an excellent read thanks for posting H2R

[H2R]

Jan 20, 2021 8-K

Recent Developments

Acquisitions



On October 1, 2020, we completed our acquisition of CRYOPDP for a cash consideration of €49,000,000, subject to cash, net debt, working capital and other adjustments. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities mainly through entities based in the United Kingdom, the United States, the Asia-Pacific region, and India.



Also, on October 1, 2020, we completed our acquisition of MVE Biological Solutions for cash consideration of $320 million, subject to customary closing working capital and other adjustments. We financed a portion of the closing cash payment of the MVE Biological Solutions acquisition with the net proceeds of the Blackstone Private Placement, as further discussed below. MVE Biological Solutions is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE Biological Solutions has manufacturing and distribution operations in the United States, Europe, and Asia.



As a result of the acquisitions, we have approximately 625 employees: 605 full-time, 10 part-time, and 10 temporary, of which 250 are located in the Americas, 158 in Europe, the Middle East and Africa, or EMEA, and 217 in Asia Pacific, or APAC.We believe that we have assembled a strong management/leadership team with the experience and expertise needed to execute our business strategy. We anticipate hiring additional personnel as needs dictate to implement our global growth strategy.



After the acquisitions, we lease or own various corporate, research and development, biostorage, global logistics and supply chain centers at 37 total sites across the Americas, EMEA and APAC regions. We believe that these facilities are adequate, suitable and of sufficient capacity to support our immediate and expected needs.



Blackstone Private Placement



In connection with the MVE Biological Solutions acquisition, on October 1, 2020, we completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc., consisting of the issuance and sale of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share, or the Series C Convertible Preferred Stock, at a price of $1,000 per share, for $250 million, and (ii) 675,536 shares of our common stock for $25.0 million, for an aggregate purchase price of $275.0 million, pursuant to a Securities Purchase Agreement, dated August 24, 2020, between us and Blackstone Freeze Parent L.P. (f/k/a BTO Freeze Parent L.P.).



Preliminary Estimates for the Three Months Ended December 31, 2020



While we have not finalized our full financial results as of and for the quarter ended December 31, 2020, we expect to report that our total revenue for the three months ended December 31, 2020 to be between $47.7 million and $48.5 million, as compared to $9.2 million for the three months ended December 31, 2019.

The expected total revenue is based on expected revenues for each of Cryoport Systems, LLC, Cryogene, MVE Biological Solutions and CRYOPDP, which we expect to be between $11.1 million and $11.2 million for Cryoport Systems, $1.4 million for Cryogene, between $22.6 million and $23.0 million for MVE Biological Solutions, and between $12.6 million and $12.9 million for CRYOPDP, respectively.

The estimated increase in total revenue was primarily attributable to growth in the Pharma/Biopharma market. We are not at this time able to estimate the amount of our operating loss or net loss, although we expect them to be substantial for the quarter and year ended December 31, 2020 due, in part, to purchase price adjustments associated with our acquisitions of CRYOPDP and MVE Biological Solutions.

http://otp.investis.com/clients/us/cryoport/SEC/sec-show.aspx?Type=html&FilingId=14628488&Cik=0001124524

Best of luck with your investments!

[H2R]

New SoS on CYRX

I continue to believe that this is one of the most exciting growth stories in biopharma and the best is yet to come. I continue to believe that the stock has dramatic upside over the next few years.

The article gives some insight in the cash position and the growth:


https://smithonstocks.com/cryoport-comments-on-just-completed-equity-offering-and-surprising-15-surge-in-stock-price-cyrx-buy-73-75/

Best of luck with your investments!

[wickerman]

$CYRX likely sees $100 soon the way that offering was swallowed in a day and the explosion of incoming demand. I have those Calls and also some $90's.

Very few publicly traded companies in temperature-controlled biostorage for the $MRNA vaccine.

$RSCF is their peer that needs to be up listed in a hurry.

https://www.cryoport.com/biological-shipping-blog/safety-measures-during-coronavirus-pandemic

[H2R]

Flirting with $80...

My best stock of the last couple of years. Thanks to Smith On Stocks' analysis.

Good luck with your investments!

[H2R]

Flirting with $70 / share.

This has been my best investment on the last couple of years, thanks to SmithOnStocks' analysis of the potential.

Best of luck with your investments!

[H2R]

From PhIII to Commercial Growth Chart



Best of luck with your investments.

[H2R]

BAM! 18% up, close: $67.35

I'll be on the lookout for news as to why this PPS action today.

Best of luck with your investments!

[restripe]

Why didn’t they get involved with Covid transportation

[H2R]

Blurb about CCRM Fertility/CYRX and today's PPS action:

Cryoport Inc. Shares Up Nearly 10% on Deal With Fertility Clinic
BY Dow Jones & Company, Inc.
— 1:16 PM ET 12/16/2020

Shares of CryoPort Inc. ( CYRX ) gained 9.5% to $52 in midday trading after the biotech freezer supply chain company said it struck a three-year deal with the Colorado Center for Reproductive Medicine.

Cryoport's ( CYRX ) logistics cold chain, which is being used to ship and store some Covid-19 vaccines, will process the fertility clinic's cryogenic shipments of human eggs and embryos used in-vitro fertilization treatments.

The Nashville, Tenn.-based company said it expects its equipment will be used to ship eggs and embryos at -80 degrees Centigrade.

The clinic has 11 labs and 26 sites in North America staffed by 40 doctors, 22 professors and 560 employees, Cryoport ( CYRX ) said.

Write to Patrick Chu at [e-mail]


(END) Dow Jones Newswires
12-16-20 1316ET
Copyright (c) 2020 Dow Jones & Company, Inc.

[Trend-Setter]

Covid-19 vaccine: cryogenic containers to play key role

https://www.gasworld.com/covid-19-vaccine-cryogenic-containers-to-play-key-role/2020141.article

[Trend-Setter]

Totally understandable. No worries! You could have made a ton of $$$ now if you at least consider investing. It's a real company with real products in the market emerging at the right time and space. Did you know there's bunch of big companies in pink sheet? Astellas Pharma of Japan, Roche, just to name a few. Good luck here!